{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T06:03:22Z","timestamp":1773554602954,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Early Cancer Screening Project in Foshan City, Guangdong Province","award":["2020G011"],"award-info":[{"award-number":["2020G011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02270-7","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:52:55Z","timestamp":1741099975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Investigation of the mechanism by which FOXJ2 inhibits proliferation, metastasis and cell cycle progression of ovarian cancer cells through the PI3K\/AKT signaling pathway"],"prefix":"10.1186","volume":"30","author":[{"given":"Liyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiyun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengrong","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"2270_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.semcancer.2022.03.027","volume":"86","author":"E Schoutrop","year":"2022","unstructured":"Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, et al. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semin Cancer Biol. 2022;86:207\u201323.","journal-title":"Semin Cancer Biol"},{"key":"2270_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1007\/s12094-019-02276-8","volume":"22","author":"HD Liu","year":"2020","unstructured":"Liu HD, Xia BR, Jin MZ, Lou G. Organoid of ovarian cancer: genomic analysis and drug screening. Clin Transl Oncol. 2020;22:1240\u201351.","journal-title":"Clin Transl Oncol"},{"key":"2270_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.32604\/oncologie.2020.013707","volume":"22","author":"N Duzkale","year":"2020","unstructured":"Duzkale N, Teker H-T. The relationship <i>BRCA1\/2<\/i> genes and family history in ovarian cancers. Oncologie. 2020;22:65\u201374.","journal-title":"Oncologie"},{"key":"2270_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.32604\/biocell.2024.047812","volume":"48","author":"L Ma","year":"2024","unstructured":"Ma L, Shao W, Zhu W. Exploring the molecular mechanisms and potential therapeutic strategies of ferroptosis in ovarian cancer. Biocell. 2024;48:379\u201386.","journal-title":"Biocell"},{"key":"2270_CR5","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.32604\/biocell.2023.027201","volume":"47","author":"Y Wang","year":"2023","unstructured":"Wang Y, Fan P, Feng Y, Yao X, Peng Y, Wang R. Clinical implication of naive and memory T cells in locally advanced cervical cancer: a proxy for tumor biology and short-term response prediction. Biocell. 2023;47:1365\u201375.","journal-title":"Biocell"},{"key":"2270_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1515\/oncologie-2022-1001","volume":"25","author":"S Deng","year":"2023","unstructured":"Deng S, Xu Y, Gao B, Yu T, Kuang L, Ba H, et al. Anemarrhenasaponin I suppresses ovarian cancer progression via inhibition of SHH signaling pathway. Oncologie. 2023;25:233\u201343.","journal-title":"Oncologie."},{"key":"2270_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1515\/oncologie-2023-0242","volume":"26","author":"X Liu","year":"2024","unstructured":"Liu X, Chen X, Liu L, Xia J, Zhang H. AKAP12 inhibits the proliferation of ovarian cancer by activating the Hippo pathway. Oncologie. 2024;26:105\u201316.","journal-title":"Oncologie"},{"key":"2270_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.semcancer.2022.03.028","volume":"86","author":"S Bose","year":"2022","unstructured":"Bose S, Saha P, Chatterjee B, Srivastava AK. Chemokines driven ovarian cancer progression, metastasis and chemoresistance: potential pharmacological targets for cancer therapy. Semin Cancer Biol. 2022;86:568\u201379.","journal-title":"Semin Cancer Biol"},{"key":"2270_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bpobgyn.2021.09.002","volume":"78","author":"GE Wood","year":"2022","unstructured":"Wood GE, Ledermann JA. Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2022;78:64\u201373.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2270_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biom14050585","author":"C Lliberos","year":"2024","unstructured":"Lliberos C, Richardson G, Papa A. Oncogenic pathways and targeted therapies in ovarian cancer. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/biom14050585.","journal-title":"Biomolecules"},{"key":"2270_CR11","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/0008-5472.CAN-21-3371","volume":"82","author":"M Castaneda","year":"2022","unstructured":"Castaneda M, Hollander PD, Mani SA. Forkhead box transcription factors: double-edged swords in cancer. Cancer Res. 2022;82:2057\u201365.","journal-title":"Cancer Res"},{"key":"2270_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104667","volume":"299","author":"L Moparthi","year":"2023","unstructured":"Moparthi L, Koch S. FOX transcription factors are common regulators of Wnt\/\u03b2-catenin-dependent gene transcription. J Biol Chem. 2023;299: 104667.","journal-title":"J Biol Chem"},{"key":"2270_CR13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/1479-7364-4-5-345","volume":"4","author":"BC Jackson","year":"2010","unstructured":"Jackson BC, Carpenter C, Nebert DW, Vasiliou V. Update of human and mouse forkhead box (FOX) gene families. Hum Genom. 2010;4:345\u201352.","journal-title":"Hum Genom"},{"key":"2270_CR14","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/cas.16120","volume":"115","author":"L Tan","year":"2024","unstructured":"Tan L, Wang S, Huang S, Tie Y, Sai N, Mao Y, et al. FoxO1 promotes ovarian cancer by increasing transcription and METTL14-mediated m(6)A modification of SMC4. Cancer Sci. 2024;115:1224\u201340.","journal-title":"Cancer Sci"},{"key":"2270_CR15","doi-asserted-by":"crossref","first-page":"101042831770621","DOI":"10.1177\/1010428317706210","volume":"39","author":"LL Wang","year":"2017","unstructured":"Wang LL, Xiu YL, Chen X, Sun KX, Chen S, Wu DD, et al. The transcription factor FOXA1 induces epithelial ovarian cancer tumorigenesis and progression. Tumour Biol. 2017;39:1010428317706210.","journal-title":"Tumour Biol"},{"key":"2270_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123065","author":"C Liu","year":"2021","unstructured":"Liu C, Barger CJ, Karpf AR. FOXM1: a multifunctional oncoprotein and emerging therapeutic target in ovarian cancer. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13123065.","journal-title":"Cancers (Basel)"},{"key":"2270_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0925-4773(00)00410-X","volume":"97","author":"B Granadino","year":"2000","unstructured":"Granadino B, Arias-de-la-Fuente C, P\u00e9rez-S\u00e1nchez C, P\u00e1rraga M, L\u00f3pez-Fern\u00e1ndez LA, del Mazo J, et al. Fhx (Foxj2) expression is activated during spermatogenesis and very early in embryonic development. Mech Dev. 2000;97:157\u201360.","journal-title":"Mech Dev"},{"key":"2270_CR18","first-page":"731","volume":"52","author":"G Guo","year":"2022","unstructured":"Guo G, Zhu L. FOXJ2 inhibits the proliferation, migration and epithelial-mesenchymal transition of prostate carcinoma cells. Ann Clin Lab Sci. 2022;52:731\u201340.","journal-title":"Ann Clin Lab Sci"},{"key":"2270_CR19","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.923559","volume":"26","author":"Y Qiang","year":"2020","unstructured":"Qiang Y, Feng L, Wang G, Liu J, Zhang J, Xiang L, et al. miR-20a\/Foxj2 axis mediates growth and metastasis of colorectal cancer cells as identified by integrated analysis. Med Sci Monit. 2020;26: e923559.","journal-title":"Med Sci Monit"},{"key":"2270_CR20","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.2147\/OTT.S134915","volume":"10","author":"Y Shan","year":"2017","unstructured":"Shan Y, Chang T, Shi S, Tang M, Bao L, Li L, et al. Foxj2 overexpression is associated with poor prognosis, progression, and metastasis in nasopharyngeal carcinoma. Onco Target Ther. 2017;10:3733\u201341.","journal-title":"Onco Target Ther"},{"key":"2270_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024759","volume":"100","author":"Y Li","year":"2021","unstructured":"Li Y, Zhu X, Liu C, Han Q, Chen X, Liu Y, et al. Low FOXJ2 expression is associated with unfavorable postoperative prognosis of patients with epithelial ovarian cancer. Medicine (Baltimore). 2021;100: e24759.","journal-title":"Medicine (Baltimore)"},{"key":"2270_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/15685551.2022.2033432","volume":"25","author":"J Zhao","year":"2022","unstructured":"Zhao J, Du L. Therapeutic effect of two transition metal coordination polymers on ovarian cancer by regulating the expression of estrogen receptor. Des Monomers Polym. 2022;25:19\u201324.","journal-title":"Des Monomers Polym"},{"key":"2270_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1874467215666220308122716","volume":"16","author":"X Peng","year":"2023","unstructured":"Peng X, Wu X, Wu G, Peng C, Huang B, Huang M, et al. MiR-129-2-3p inhibits esophageal carcinoma cell proliferation, migration, and invasion via targeting DNMT3B. Curr Mol Pharmacol. 2023;16:116\u201323.","journal-title":"Curr Mol Pharmacol"},{"key":"2270_CR24","doi-asserted-by":"publisher","first-page":"1133476","DOI":"10.3389\/fonc.2023.1133476","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, Tan Z, Li X, Zhang L, Pei X. RUNX2 promotes gastric cancer progression through the transcriptional activation of MGAT5 and MMP13. Front Oncol. 2023;13:1133476.","journal-title":"Front Oncol"},{"key":"2270_CR25","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1111\/cas.13083","volume":"107","author":"J Zou","year":"2016","unstructured":"Zou J, Hong L, Luo C, Li Z, Zhu Y, Huang T, et al. Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway. Cancer Sci. 2016;107:1806\u201317.","journal-title":"Cancer Sci"},{"key":"2270_CR26","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.2174\/1874467215666220124125809","volume":"15","author":"SM Manohar","year":"2022","unstructured":"Manohar SM, Joshi KS. Promising anticancer activity of multitarget cyclin dependent kinase inhibitors against human colorectal carcinoma cells. Curr Mol Pharmacol. 2022;15:1024\u201333.","journal-title":"Curr Mol Pharmacol"},{"key":"2270_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"2270_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1515\/oncologie-2023-0172","volume":"25","author":"A Mazidimoradi","year":"2023","unstructured":"Mazidimoradi A, Momenimovahed Z, Khani Y, Shahrabi AR, Allahqoli L, Salehiniya H. Global patterns and temporal trends in ovarian cancer morbidity, mortality, and burden from 1990 to 2019. Oncologie. 2023;25:641\u201359.","journal-title":"Oncologie"},{"key":"2270_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/978-3-030-34025-4_18","volume":"1219","author":"VDB Bonif\u00e1cio","year":"2020","unstructured":"Bonif\u00e1cio VDB. Ovarian cancer biomarkers: moving forward in early detection. Adv Exp Med Biol. 2020;1219:355\u201363.","journal-title":"Adv Exp Med Biol"},{"key":"2270_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.32604\/oncologie.2020.012491","volume":"22","author":"G Chen","year":"2020","unstructured":"Chen G, Xie T, Chen H, Chen L. Expression and clinical significance of miR-152 and CYFRA21-1 in ovarian cancer tissues. Oncologie. 2020;22:83\u201393.","journal-title":"Oncologie"},{"key":"2270_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jcp.22248","volume":"225","author":"AV Sirotkin","year":"2010","unstructured":"Sirotkin AV. Transcription factors and ovarian functions. J Cell Physiol. 2010;225:20\u20136.","journal-title":"J Cell Physiol"},{"key":"2270_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0022-2836(03)00524-2","volume":"329","author":"MA G\u00f3mez-Ferrer\u00eda","year":"2003","unstructured":"G\u00f3mez-Ferrer\u00eda MA, Rey-Campos J. Functional domains of FOXJ2. J Mol Biol. 2003;329:631\u201344.","journal-title":"J Mol Biol"},{"issue":"Suppl","key":"2270_CR33","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.semcancer.2015.02.006","volume":"35","author":"MA Feitelson","year":"2015","unstructured":"Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, et al. Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015;35(Suppl):S25-s54.","journal-title":"Semin Cancer Biol"},{"key":"2270_CR34","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell. 2023;186:1564\u201379.","journal-title":"Cell"},{"key":"2270_CR35","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/sj.onc.1210319","volume":"26","author":"K Kehn","year":"2007","unstructured":"Kehn K, Berro R, Alhaj A, Bottazzi ME, Yeh WI, Klase Z, et al. Functional consequences of cyclin D1\/BRCA1 interaction in breast cancer cells. Oncogene. 2007;26:5060\u20139.","journal-title":"Oncogene"},{"key":"2270_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.prp.2015.01.005","volume":"211","author":"X Qiu","year":"2015","unstructured":"Qiu X, Ji B, Yang L, Huang Q, Shi W, Ding Z, et al. The role of FoxJ2 in the migration of human glioma cells. Pathol Res Pract. 2015;211:389\u201397.","journal-title":"Pathol Res Pract"},{"key":"2270_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/cbin.10680","volume":"41","author":"Q Yang","year":"2017","unstructured":"Yang Q, Cao X, Tao G, Zhou F, Zhao P, Shen Y, et al. Effects of FOXJ2 on TGF-\u03b21-induced epithelial-mesenchymal transition through notch signaling pathway in non-small lung cancer. Cell Biol Int. 2017;41:79\u201383.","journal-title":"Cell Biol Int"},{"key":"2270_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol. 2019;59:147\u201360.","journal-title":"Semin Cancer Biol"},{"key":"2270_CR39","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","volume":"23","author":"DA Altomare","year":"2004","unstructured":"Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23:5853\u20137.","journal-title":"Oncogene"},{"key":"2270_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5732\/cjc.014.10289","volume":"34","author":"B Cheaib","year":"2015","unstructured":"Cheaib B, Auguste A, Leary A. The PI3K\/Akt\/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer. 2015;34:4\u201316.","journal-title":"Chin J Cancer"},{"key":"2270_CR41","doi-asserted-by":"publisher","first-page":"8213","DOI":"10.3390\/ijms14048213","volume":"14","author":"ZC Dobbin","year":"2013","unstructured":"Dobbin ZC, Landen CN. The importance of the PI3K\/AKT\/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013;14:8213\u201327.","journal-title":"Int J Mol Sci"},{"key":"2270_CR42","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.cellsig.2006.05.019","volume":"18","author":"Q Meng","year":"2006","unstructured":"Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 2006;18:2262\u201371.","journal-title":"Cell Signal"},{"key":"2270_CR43","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/gcc.20883","volume":"50","author":"J Huang","year":"2011","unstructured":"Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, et al. Frequent genetic abnormalities of the PI3K\/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosom Cancer. 2011;50:606\u201318.","journal-title":"Genes Chromosom Cancer"},{"key":"2270_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ygyno.2023.01.038","volume":"171","author":"CSE Hendrikse","year":"2023","unstructured":"Hendrikse CSE, Theelen PMM, van der Ploeg P, Westgeest HM, Boere IA, Thijs AMJ, et al. The potential of RAS\/RAF\/MEK\/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2023;171:83\u201394.","journal-title":"Gynecol Oncol"},{"key":"2270_CR45","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1111\/jog.15761","volume":"49","author":"I Yunianto","year":"2023","unstructured":"Yunianto I, Currie M, Chitcholtan K, Sykes P. Potential drug repurposing of ruxolitinib to inhibit the JAK\/STAT pathway for the treatment of patients with epithelial ovarian cancer. J Obstet Gynaecol Res. 2023;49:2563\u201374.","journal-title":"J Obstet Gynaecol Res"},{"key":"2270_CR46","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1111\/jcmm.14325","volume":"23","author":"S Li","year":"2019","unstructured":"Li S, Lv M, Qiu S, Meng J, Liu W, Zuo J, et al. NF-\u03baB p65 promotes ovarian cancer cell proliferation and migration via regulating mortalin. J Cell Mol Med. 2019;23:4338\u201348.","journal-title":"J Cell Mol Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02270-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02270-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02270-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T15:46:44Z","timestamp":1741103204000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02270-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2270"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02270-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}